ClinicalTrials.gg
CompletedNCT04311411Updated May 22, 2024Results posted

A Study of Tirzepatide in Overweight and Very Overweight Participants

A Phase 1 interventional study of Tirzepatide and Placebo in Obesity and Overweight, sponsored by Eli Lilly and Company. Completed at 3 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-05-22.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 104 studies testing tirzepatide in Obesity — 60 open to participants now, 79 under way, 14 of them phase 3. Tirzepatide · Obesity.

Enrollment
47th of 104
114 · median 69
Started
2020
with 2 others
Phase 1
12 of 104
5 open now
Registered
3rd of 104
by date
Lead sponsor
34 of 104
Eli Lilly and Company

Among the 104 studies testing tirzepatide in Obesity, this one is the 47th largest by enrollment, is one of 3 that started in 2020, is one of 12 in phase 1, and was the 3rd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

60 of the 104 studies testing tirzepatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

55 more — sign in →

By country, each count listing its studies:

All 60 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing tirzepatide in Obesity, or all of them as a file.
02

Study summary

The main purpose of this study is to measure the effect of tirzepatide on food intake in participants who are overweight or very overweight. The study will also use imaging to learn more about how tirzepatide affects specific parts of the brain. The effect of tirzepatide on appetite will also be studied. The study will last up to about four months and will include up to 14 visits to the study center.

03

Conditions studied

  • Obesity
  • Overweight
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have stable body weight for the past 1 month prior to screening
  • Have a (BMI) between 27 to 50 kilograms per meter squared (kg/m²), inclusive at screening
  • Willing and agreeable to commit to the duration of the study and undergo study procedures as instructed by the clinic staff
  • Women must not be pregnant or breastfeeding

Exclusion criteria

Exclusion Criteria:

  • Have undergone or plan to undergo gastric bypass or bariatric surgery
  • Have claustrophobia or have ferromagnetic implants that can interfere with completion of fMRI measurements
  • Have other medical conditions or medical history that make participation in the study unsafe or which may interfere in the interpretation of the results of the study
  • Unwilling to comply with smoking and alcohol restrictions during the study
  • Have received prescription drugs or over the counter drugs that promote weight loss in the past 6 months prior to screening
  • Have a diagnosis of type 2 diabetes
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
114 participants (actual)

Study arms

  • Experimental
    Tirzepatide

    Participants received tirzepatide 5 milligrams (mg) once a week (QW) for Weeks 1 through 3 followed by tirzepatide 10 mg QW for Weeks 4 through 6 into the subcutaneous (SC) tissue of the abdominal wall.

    Drug: Tirzepatide

  • Placebo comparator
    Placebo

    Participants received placebo administered into the SC tissue of the abdominal wall.

    Drug: Placebo

  • Active comparator
    Liraglutide

    Participants received Liraglutide with step wise dose escalation regimen starting from 0.6 mg once daily (QD) for week 1 followed by 1.2 mg QD for week 2, 1.8 mg QD for week 3, 2.4 mg QD for Week 4 followed by 3 mg QD starting in Week 5 and maintained for 10 days administered into the SC tissue of the abdominal wall.

    Drug: Liraglutide

Interventions

  • Administered SC.

    Also known as: LY3298176

  • DrugPlacebo

    Administered SC.

  • Administered SC.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Calorie Intake in Participants Receiving Tirzepatide or Placebo at Week 3

    Change from baseline in calorie intake in participants receiving tirzepatide or placebo at week 3 is reported.

    Time frame: Baseline, Week 3

Secondary outcomes

  1. Change From Baseline in Blood Oxygen Level-dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signals in Response to Images of Highly Palatable Food Relative to Nonfood Item During Fasting State in the 5 Brain Reward Areas

    Change from baseline in BOLD fMRI signals in response to images of highly palatable foods (high fat-high sugar and high fat-high carbohydrate) relative to nonfood items during the fasting state in the brain reward areas (Insula, medial frontal gyrus, superior temporal gyrus, precentral gyrus, and cingulate gyrus) at Week 3 is reported. fMRI is a functional neuroimaging procedure that uses MRI technology to measure brain activity by detecting associated changes in blood flow. When an area of the brain is in use, blood flow to that region increases. The activation in response to the processing of viewing food images in each brain reward areas was measured by the signal change in BOLD response. Least squares (LS) mean was calculated using mixed-model repeated measures (MMRM) model with covariates Baseline + Treatment + Baseline Body mass index (BMI) Stratum + Scanner Identification + Week + Treatment\*Week + Participant + Random Error.

    Time frame: Baseline, Week 3

  2. Change From Baseline in Fasting and Postprandial Overall Appetite Visual Analog Scale (VAS) Score

    The VAS determines the effects on appetite sensations and desire for specific foods. It consists of 8 individual questions that measure hunger, satiety, fullness, prospective food consumption, desire for sweet food, desire for salty food, desire for savory food, and desire for fatty food. The VAS scales will be analyzed as continuous variables on the 0-100 scale for 8 individual components. Hunger, satiety, fullness, prospective food consumption are rated as 0=Not at all and 100=Extremely. Desire for sweet food, desire for salty food, desire for savory food, and desire for fatty food are rated as 0=Yes, very much and 100=No, not at all. Overall appetite score is calculated as the average of the first 4 individual scores (satiety + fullness + \[100-prospective food consumption\] + \[100-hunger\]/4). The higher overall appetite score indicates less appetite, and the lower score indicates more appetite.

    Time frame: Baseline, Week 3

07

Results

Posted May 22, 2024

Participant flow

Participant flow — Overall Study
MilestonePlaceboTirzepatideLiraglutide
Started393738
Received at least one dose of study drug393738
Completed343136
Not completed562
Withdrew: Adverse event232
Withdrew: Withdrawal by subject330

Outcome measures

PrimaryChange From Baseline in Calorie Intake in Participants Receiving Tirzepatide or Placebo at Week 3

Change from baseline in calorie intake in participants receiving tirzepatide or placebo at week 3 is reported.

Time frame:
Baseline, Week 3
Reported as:
Least squares mean · kilocalories (kcal)
Change From Baseline in Calorie Intake in Participants Receiving Tirzepatide or Placebo at Week 3
kilocalories (kcal)PlaceboTirzepatide
Change From Baseline in Calorie Intake in Participants Receiving Tirzepatide or Placebo at Week 310.95 ± 49.06-523.15 ± 52.78
Statistical analysis
  • Placebo vs Tirzepatide · ANCOVA · p = <.0001 · Median difference (final values): -534.11 · 95% CI -668.20 to -400.02
SecondaryChange From Baseline in Blood Oxygen Level-dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signals in Response to Images of Highly Palatable Food Relative to Nonfood Item During Fasting State in the 5 Brain Reward Areas

Change from baseline in BOLD fMRI signals in response to images of highly palatable foods (high fat-high sugar and high fat-high carbohydrate) relative to nonfood items during the fasting state in the brain reward areas (Insula, medial frontal gyrus, superior temporal gyrus, precentral gyrus, and cingulate gyrus) at Week 3 is reported. fMRI is a functional neuroimaging procedure that uses MRI technology to measure brain activity by detecting associated changes in blood flow. When an area of the brain is in use, blood flow to that region increases. The activation in response to the processing of viewing food images in each brain reward areas was measured by the signal change in BOLD response. Least squares (LS) mean was calculated using mixed-model repeated measures (MMRM) model with covariates Baseline + Treatment + Baseline Body mass index (BMI) Stratum + Scanner Identification + Week + Treatment\*Week + Participant + Random Error.

Time frame:
Baseline, Week 3
Reported as:
Least squares mean · Arbitrary Units
Change From Baseline in Blood Oxygen Level-dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signals in Response to Images of Highly Palatable Food Relative to Nonfood Item During Fasting State in the 5 Brain Reward Areas
Arbitrary UnitsPlaceboTirzepatideLiraglutide
Insula-0.0739 ± 0.0740-0.0301 ± 0.07710.0190 ± 0.0738
Medial frontal gyrus0.0504 ± 0.06490.0494 ± 0.06800.0581 ± 0.0658
Superior temporal gyrus0.0132 ± 0.08380.0174 ± 0.08810.0621 ± 0.0839
Precentral gyrus0.0441 ± 0.05800.0249 ± 0.06160.0845 ± 0.0593
Cingulate gyrus0.0283 ± 0.06150.0214 ± 0.06430.0967 ± 0.0623
Statistical analysis
  • Placebo vs Tirzepatide · Mixed Models Analysis · p = 0.5437 · Median difference (final values): 0.0439 · 95% CI -0.0994 to 0.1871
  • Placebo vs Liraglutide · Mixed Models Analysis · p = 0.1806 · Mean difference (final values): 0.0930 · 95% CI -0.0441 to 0.2301
  • Tirzepatide vs Liraglutide · Mixed Models Analysis · p = 0.4720 · Mean difference (final values): -0.0491 · 95% CI -0.1846 to 0.0863
  • Placebo vs Tirzepatide · Mixed Models Analysis · p = 0.9842 · Mean difference (final values): -0.0011 · 95% CI -0.1079 to 0.1058
  • Placebo vs Liraglutide · Mixed Models Analysis · p = 0.8822 · Mean difference (final values): 0.0077 · 95% CI -0.0949 to 0.1102
  • Tirzepatide vs Liraglutide · Mixed Models Analysis · p = 0.8657 · Mean difference (final values): -0.0087 · 95% CI -0.1111 to 0.0937
  • Placebo vs Tirzepatide · Mixed Models Analysis · p = 0.9599 · Mean difference (final values): 0.0043 · 95% CI -0.1650 to 0.1736
  • Placebo vs Liraglutide · Mixed Models Analysis · p = 0.5490 · Mean difference (final values): 0.0489 · 95% CI -0.1129 to 0.2107
  • Tirzepatide vs Liraglutide · Mixed Models Analysis · p = 0.5854 · Mean difference (final values): -0.0446 · 95% CI -0.2068 to 0.1176
  • Placebo vs Tirzepatide · Mixed Models Analysis · p = 0.7203 · Mean difference (final values): -0.0192 · 95% CI -0.1259 to 0.0874
  • Placebo vs Liraglutide · Mixed Models Analysis · p = 0.4330 · Mean difference (final values): 0.0404 · 95% CI -0.0617 to 0.1425
  • Tirzepatide vs Liraglutide · Mixed Models Analysis · p = 0.2488 · Mean difference (final values): -0.0596 · 95% CI -0.1619 to 0.0426
  • Placebo vs Tirzepatide · Mixed Models Analysis · p = 0.8886 · Mean difference (final values): -0.0070 · 95% CI -0.1059 to 0.0919
  • Placebo vs Liraglutide · Mixed Models Analysis · p = 0.1563 · Mean difference (final values): 0.0684 · 95% CI -0.0267 to 0.1635
  • Tirzepatide vs Liraglutide · Mixed Models Analysis · p = 0.1182 · Mean difference (final values): -0.0754 · 95% CI -0.1704 to 0.0196
SecondaryChange From Baseline in Fasting and Postprandial Overall Appetite Visual Analog Scale (VAS) Score

The VAS determines the effects on appetite sensations and desire for specific foods. It consists of 8 individual questions that measure hunger, satiety, fullness, prospective food consumption, desire for sweet food, desire for salty food, desire for savory food, and desire for fatty food. The VAS scales will be analyzed as continuous variables on the 0-100 scale for 8 individual components. Hunger, satiety, fullness, prospective food consumption are rated as 0=Not at all and 100=Extremely. Desire for sweet food, desire for salty food, desire for savory food, and desire for fatty food are rated as 0=Yes, very much and 100=No, not at all. Overall appetite score is calculated as the average of the first 4 individual scores (satiety + fullness + \[100-prospective food consumption\] + \[100-hunger\]/4). The higher overall appetite score indicates less appetite, and the lower score indicates more appetite.

Time frame:
Baseline, Week 3
Reported as:
Least squares mean · score on a scale
Change From Baseline in Fasting and Postprandial Overall Appetite Visual Analog Scale (VAS) Score
score on a scalePlaceboTirzepatideLiraglutide
Fasting (Pre-lunch)2.15 ± 3.0222.72 ± 3.308.78 ± 3.11
Postprandial (Post-lunch)-0.59 ± 2.081.66 ± 2.230.05 ± 2.12
Statistical analysis
  • Placebo vs Tirzepatide · Mixed Models Analysis · p = <.0001 · Mean difference (final values): 20.57 · 95% CI 12.11 to 29.02
  • Placebo vs Liraglutide · Mixed Models Analysis · p = 0.1097 (Fasting) · Mean difference (final values): 6.63 · 95% CI -1.53 to 14.79
  • Tirzepatide vs Liraglutide · Mixed Models Analysis · p = 0.0015 · Mean difference (final values): 13.94 · 95% CI 5.49 to 22.38
  • Placebo vs Tirzepatide · Mixed Models Analysis · p = 0.4469 · Mean difference (final values): 2.25 · 95% CI -3.60 to 8.09
  • Placebo vs Liraglutide · Mixed Models Analysis · p = 0.8227 · Mean difference (final values): 0.64 · 95% CI -5.02 to 6.31
  • Tirzepatide vs Liraglutide · Mixed Models Analysis · p = 0.5861 · Mean difference (final values): 1.61 · 95% CI -4.23 to 7.45

Adverse events

Collected over Baseline up to 10 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/39 (0%)0/39 (0%)11/39 (28.2%)
Tirzepatide0/37 (0%)0/37 (0%)29/37 (78.4%)
Liraglutide0/38 (0%)1/38 (2.6%)20/38 (52.6%)
Most frequent serious events
Most frequent serious events
EventPlaceboTirzepatideLiraglutide
COVID-19 pneumoniaInfections and infestations0/390/371/38
Most frequent other events
Showing 10 of 16
Most frequent other events
EventPlaceboTirzepatideLiraglutide
NauseaGastrointestinal disorders2/3919/3711/38
VomitingGastrointestinal disorders1/3911/374/38
ConstipationGastrointestinal disorders0/397/375/38
DyspepsiaGastrointestinal disorders1/397/372/38
HeadacheNervous system disorders3/397/373/38
Abdominal distensionGastrointestinal disorders0/395/371/38
DiarrhoeaGastrointestinal disorders2/395/371/38
Abdominal pain upperGastrointestinal disorders1/394/371/38
FlatulenceGastrointestinal disorders2/394/372/38
Injection site reactionGeneral disorders1/394/371/38

Baseline characteristics

All participants who were randomized and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)PlaceboTirzepatideLiraglutideTotal
Mean46.2 ± 9.544.8 ± 10.243.7 ± 11.944.9 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTirzepatideLiraglutideTotal
Female36362597
Male311317
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboTirzepatideLiraglutideTotal
Hispanic or Latino2035
Not Hispanic or Latino373635108
Unknown or Not Reported0101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboTirzepatideLiraglutideTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American1191030
White28272883
More than one race0101
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)PlaceboTirzepatideLiraglutideTotal
United States393738114
08

Study locations

3 sites
  • Indiana University School of Medicine
    Indianapolis, Indiana 46202, United States
  • Pennington Biomedical Research Center
    Baton Rouge, Louisiana 70808, United States
  • Johns Hopkins University School of Medicine
    Baltimore, Maryland 21287, United States
09

References and documents

Publications

  • Martin CK, Carmichael OT, Carnell S, Considine RV, Kareken DA, Dydak U, Mattes RD, Scott D, Shcherbinin S, Nishiyama H, Knights A, Urva S, Biernat L, Pratt E, Haupt A, Mintun M, Otero Svaldi D, Milicevic Z, Coskun T. Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Nat Med. 2025 Sep;31(9):3141-3150. doi: 10.1038/s41591-025-03774-9. Epub 2025 Jun 24. PubMed 40555748 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Dec 2022, 27 months.

Results were first posted in May 2024, 1 year 5 months after primary completion.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 27 months is above that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2020
First posted
Mar 17, 2020
StartActual
Aug 24, 2020
Primary completionActual
Dec 16, 2022
CompletionActual
Dec 16, 2022
Results first posted
May 22, 2024
Last update
May 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04311411
Responsible party
Sponsor
First posted
Mar 17, 2020
Start date
Aug 24, 2020
Primary completion
Dec 16, 2022
Completion
Dec 16, 2022
Results posted
May 22, 2024
Last update
May 22, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion